Elevated DNA methylation across a 48-kb region spanning the HOXA gene cluster is associated with Alzheimer's disease neuropathology by Smith, Rebecca G. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.jalz.2018.01.017
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Smith, R. G., Hannon, E., De Jager, P. L., Chibnik, L., Lott, S. J., Condliffe, D., ... Lunnon, K. (2018). Elevated
DNA methylation across a 48-kb region spanning the HOXA gene cluster is associated with Alzheimer's disease
neuropathology. Alzheimer's & Dementia. DOI: 10.1016/j.jalz.2018.01.017
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 21. Mar. 2018
Abbreviations 
 
Alzheimer’s disease (AD); Cerebellum (CER); Differentially methylated position (DMP); 
Differentially methylated region (DMR); Down syndrome (DS); Entorhinal cortex (EC); Epigenome-
wide association study (EWAS); Illumina Infinium Human Methylation 450K BeadChip (450K 
array); Prefrontal cortex (PFC); Quality control (QC); Reference Sequence (RefSeq); Single 
nucleotide polymorphism (SNP); Superior temporal gyrus (STG) 
RESEARCH ARTICLE 1 
Elevated DNA methylation across a 48kb region spanning the HOXA gene cluster is 2 
associated with Alzheimer’s disease neuropathology. 3 
Rebecca G. Smith
a
, Eilis Hannon
a
, Philip L. De Jager
b,c,d
, Lori Chibnik
b,c
, Simon J. Lott
e
, 4 
Daniel Condliffe
f
,
 
Adam R. Smith
a
, Vahram Haroutunian
g,h,i
, Claire Troakes
e
, Safa Al-Sarraj
e
, 5 
David A. Bennett
j
, John Powell
e
, Simon Lovestone
k
, Leonard Schalkwyk
l
, Jonathan Mill
a,m,*
, 6 
Katie Lunnon
a,m,* 7 
 
8 
a 
University of Exeter Medical School, RILD Building, Royal Devon & Exeter Hospital Campus, 9 
Barrack Road, University of Exeter, Devon, UK. 10 
b
 Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments 11 
of Neurology and Psychiatry, Brigham and Women’s Hospital, Boston, MA, USA. 12 
c
 Harvard Medical School, Boston, MA, USA. 13 
d
 Department of Neurology, Columbia University College of Physicians and Surgeons, Columbia 14 
University Medical Center, NY, USA 15 
e 
Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, 16 
London, UK. 17 
f
 Queen Mary University of London, London, UK.
 18 
g
 Department of Psychiatry, The Icahn School of Medicine at Mount Sinai, New York, USA. 19 
h
 Department of Neuroscience, The Icahn School of Medicine at Mount Sinai, New York, USA. 20 
i
 JJ Peters VA Medical Center, Bronx, New York, USA. 21 
j
 Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL, USA. 22 
k
 Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK. 23 
l 
University of Essex, Wivenhoe Park, Colchester, UK. 24 
m
 These authors contributed equally 25 
 26 
*
 Corresponding authors: 27 
Katie Lunnon: University of Exeter Medical School, RILD, Barrack Road, University of 28 
Exeter, Devon, UK. UK. Tel: + 44 1392 408 298 Email address: k.lunnon@exeter.ac.uk 29 
2 
 
Jonathan Mill: University of Exeter Medical School, RILD Building Level 4, Royal Devon 1 
and Exeter Hospital, Barrack Rd, Exeter. EX2 5DW. UK. E-mail: j.mill@exeter.ac.uk 2 
Abstract 3 
INTRODUCTION: Alzheimer’s disease is a neurodegenerative disorder that is hypothesized 4 
to involve epigenetic dysregulation of gene expression in the brain.  5 
METHODS: We performed an epigenome-wide association study to identify differential 6 
DNA methylation associated with neuropathology in prefrontal cortex and superior temporal 7 
gyrus samples from 147 individuals, replicating our findings in two independent datasets 8 
(N=117 and 740). 9 
RESULTS: We identify elevated DNA methylation associated with neuropathology across a 10 
48kb region spanning 208 CpG sites within the HOXA gene cluster. A meta-analysis of the 11 
top-ranked probe within the HOXA3 gene (cg22962123) highlighted significant 12 
hypermethylation across all three cohorts (P = 3.11 X 10
-18
).  13 
DISCUSSION: We present robust evidence for elevated DNA methylation associated with 14 
Alzheimer’s disease neuropathology spanning the HOXA gene cluster on chromosome 7. 15 
These data add to the growing evidence highlighting a role for epigenetic variation in 16 
Alzheimer’s disease, implicating the HOX gene family as a target for future investigation. 17 
 18 
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 1 
1. Introduction 2 
Alzheimer’s disease (AD), the most common form of dementia, is a progressive 3 
neurodegenerative disorder that is making an increasing contribution to the global burden of 4 
disease as the population ages [1]. AD pathology is characterized by the accumulation of 5 
amyloid (Aβ) plaques and tau tangles, ultimately leading to neuronal cell loss. The 6 
neurodegeneration associated with AD is believed to start many decades before clinical onset; 7 
during this ‘preclinical’ phase the plaque and tangle load in the brain increases until a person-8 
specific threshold level is reached and behavioral changes and cognitive impairment become 9 
manifest [2-4]. At present there are no disease-modifying treatments available, with existing 10 
medications only alleviating certain symptoms of AD. A better understanding of the 11 
underlying mechanisms precipitating the onset and progression of pathology is required to 12 
enable the design of new, more effective medications.  13 
Increased knowledge about the functional complexity of the genome has led to speculation 14 
about the role of epigenetic variation in health and disease, including for neurodegenerative 15 
diseases such as AD [5]. Two epigenome-wide association studies (EWAS) of AD [6, 7] 16 
recently identified consistent patterns of DNA methylation associated with neuropathology. 17 
Of particular interest was replicated evidence for cortex-specific hypermethylation at multiple 18 
CpG sites within ANK1, although differences at a number of other loci were identified in one, 19 
or both studies [8]. One of the previously reported neuropathology-associated differentially 20 
methylated positions (DMPs), cg22962123, is located within the HOXA gene cluster on 21 
chromosome 7 [7]. Here, we present further evidence to support a role for altered DNA 22 
methylation in AD-associated neuropathology across an extensive region spanning the HOXA 23 
cluster.  24 
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 1 
2. Methods 2 
2.1 Samples and subjects 3 
Our discovery (Mount Sinai) cohort consisted of brain tissue from 147 individuals obtained 4 
from the Mount Sinai Alzheimer's Disease and Schizophrenia Brain Bank 5 
(http://icahn.mssm.edu/research/labs/neuropathology-and-brain-banking). From the 147 6 
donors, two cortical regions (prefrontal cortex (PFC, N=144) and superior temporal gyrus 7 
(STG, N=142)) were used for the purposes of the study. All samples were dissected by 8 
trained specialists, snap-frozen and stored at −80°C. Further information about the samples is 9 
given in Supplementary Table 1. Ethical approval for the project was provided by the 10 
University of Exeter Medical School Research Ethics Committee under application number 11 
14/02/041. Genomic DNA was isolated from ~100mg of each dissected brain region using a 12 
standard phenol-chloroform extraction protocol and tested for purity and degradation prior to 13 
analysis.
  
For replication purposes we used previously published EWAS data collected in two 14 
independent cohorts on the Illumina Infinium Human Methylation 450K BeadChip (450K 15 
array); i) the “London” (Lunnon et al) cohort, consisting of PFC, STG, entorhinal cortex 16 
(EC), cerebellum (CER) and pre-mortem blood DNA methylation data from  117 individuals 17 
from the MRC London Neurodegenerative Disease Brain Bank [6], and ii) the “ROS/MAP” 18 
(De Jager et al) cohort, consisting of PFC DNA methylation data from 740 individuals from 19 
the Religious Orders Study and the Rush Memory and Aging Project [7].
 
All samples were 20 
assigned a unique code number for the experiment, which was independent of age, gender or 21 
diagnosis. This code was used throughout the experiment and analysis.
 22 
 23 
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 1 
2.2 Bisulfite treatment and Illumina Infinium BeadArray 2 
500ng genomic DNA was sodium bisulfite converted using the EZ-DNA methylation kit 3 
(Zymo Research, Orange, CA, USA) and DNA methylation was subsequently quantified 4 
using the 450K array (Illumina, USA) with arrays scanned using an Illumina iScan (software 5 
version 3.3.28). Samples were processed by tissue and randomized with respect to age and 6 
gender. The Illumina 450K array interrogates >485,000 probes covering 99% of Reference 7 
Sequence (RefSeq) genes, with an average of 17 CpG sites per gene region (distributed 8 
across promoter, 5’UTR, first exon, gene body and 3’UTR regions). It covers 96% of CpG 9 
islands, with additional coverage in island shores and their flanking regions.  10 
 11 
2.3 Microarray quality control and data normalization 12 
Initial quality control (QC) of data was conducted using GenomeStudio (version 2011.1) to 13 
determine the status of staining, extension, hybridization, target removal, sodium bisulfite 14 
conversion, specificity, non-polymorphic and negative controls. Probes previously reported to 15 
hybridize to multiple genomic regions or containing a single nucleotide polymorphism (SNP) 16 
at the single base extension site were removed from subsequent analyses [9, 10], in addition 17 
to the 65 SNPs used for sample identification on the array (total probes removed 72,067). For 18 
each probe, DNA methylation levels were indexed by beta values – i.e. the ratio of 19 
methylated signal divided by the sum of the methylated and unmethylated signal (M/M+U).  20 
 21 
2.4 Data analysis 22 
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All computations and statistical analyses were performed using R 3.0.2 and Bioconductor 1 
2.13. Signal intensities were imported into R using the methylumi package. Initial QC checks 2 
were performed using functions in the methylumi package to assess concordance between 3 
reported and genotyped gender. Non-CpG SNP probes on the array were also used to confirm 4 
that both brain regions were sourced from the same individual where expected. Data were 5 
pre-processed and quantile normalized using the dasen function as part of the wateRmelon 6 
package (wateRmelon_1.0.3) [11] within the R statistical analysis environment and batch 7 
corrected using the ComBat package [12]. Array data for each of the tissues was normalized 8 
separately and initial analyses were performed separately by tissue. Full Illumina 450K array 9 
data was available for the discovery (Mount Sinai) and London (Lunnon et al) cohorts and 10 
thus we were able to estimate neuronal proportions in the data using the R package CETS 11 
[13]. For the ROS/MAP (De Jager et al) cohort we only had Illumina 450K array data for 12 
probes in the HOXA region and thus could not calculate neuronal proportions. Therefore, the 13 
effects of age, gender and cell type composition were regressed out of the discovery (Mount 14 
Sinai) and London (Lunnon et al) cohorts, whilst the effects of age and gender only were 15 
regressed out of the ROS/MAP (De Jager et al) cohort before subsequent analysis. For 16 
identification of differentially methylated positions (DMPs) specifically altered with respect 17 
to neuropathological measures of AD, we performed a quantitative analysis in which samples 18 
were analyzed separately in each brain region using linear regression models with respect to 19 
Braak stage, with probes ranked according to P value. The genic location of identified DMPs 20 
was annotated by GREAT annotation [14]. We have previously established the multiple 21 
testing threshold (experiment-wide significance) for EWAS data generated on the Illumina 22 
450K array as P < 2.2 X 10
-7
 [15]. In brief, in this previous study 5000 permutations were 23 
performed repeating a linear regression model for randomly selected groups of cases and 24 
controls (N=675). For each permutation, P values from the EWAS were saved and the 25 
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minimum identified. Across all permutations the fifth percentile was calculated to generate 1 
the 5 % alpha significance threshold, which was deemed to be P < 2.2 X 10
-7
.
  
To identify 2 
differentially methylated regions (DMRs), we identified spatially correlated P values in our 3 
data using the Python module comb-p to group ≥3 spatially correlated CpGs in a 500-bp 4 
sliding window [16]. The coMET package was used to identify regional co-methylation 5 
patterns and regional EWAS results [17]. Fisher’s combined P value analysis was performed 6 
in the MetaDE package [18] and meta-analysis on correlation and case control status 7 
performed with the meta package [19] within R [20]. Data is available for the discovery 8 
(Mount Sinai) cohort within GEO under accession number GSE80970. The discovery (Mount 9 
Sinai) EWAS data-set has been previously used to validate the top 100 DMPs nominated in a 10 
previously published EWAS [6]. As such, we have not sought to replicate these top 100 11 
DMPs in the current study. 12 
 13 
3. Results 14 
3.1 Hypermethylation associated with AD neuropathology is observed in a region spanning 15 
48kb across the HOXA gene cluster in human cortex 16 
Our primary analyses focused on matched PFC and STG tissue from 147 individuals 17 
(Supplementary Table 1). We used the 450K array to first quantify DNA methylation in the 18 
PFC and identify DMPs associated with Braak score, a standardized measure of 19 
neurofibrillary tangle burden determined at autopsy, controlling for age, gender and estimated 20 
neuronal cell proportion. We identified ten experiment-wide significant (P < 2.2 X 10
-7
) 21 
DMPs (Table 1A and Figure 1A), with 78 DMPs associated with Braak stage at a more 22 
relaxed threshold of P < 1 X 10
-5
 (Supplementary Table 2). Of these 78 DMPs, nine were 23 
located in the HOXA gene cluster on chromosome 7, most notably in the vicinity of HOXA3, 24 
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with one HOXA DMP reaching experiment-wide significance (cg22962123: P = 1.2 X 10
-7
). 1 
We next used a sliding window approach (comb-p [16]) to identify spatially correlated 2 
regions of differential DNA methylation associated with neuropathology; Table 1B lists 3 
differentially methylated regions (DMRs) spanning at least three probes with a window size 4 
of 500bp and a Sidak-corrected P value <0.05. We identified six closely-located DMRs 5 
within the HOXA gene region, with the most significant DMR in the HOXA region spanning 6 
seven probes in a 364bp region within intron 1 of HOXA3 (Figure 1B; Sidak-corrected P = 7 
1.19 X 10
-9
). Of note, we observed an extended region of neuropathology-associated 8 
hypermethylation spanning 48,754 base pairs (bp) from upstream of the HOXA2 gene to the 9 
HOXA6 gene and covering 208 Illumina 450K array probes (Figure 1C). Given that DNA 10 
methylation at nearby CpG sites can be highly correlated [21], we visualized co-methylation 11 
patterns between CpG sites within HOXA3 using coMET [17] and observed highly correlated 12 
patterns of DNA methylation between CpG sites in this extended region (Supplementary 13 
Figure 1). We next sought to test whether neuropathology-associated DNA methylation 14 
patterns across this 48,754bp region were specific to the PFC, using the Illumina 450K array 15 
to profile STG samples from the same individuals. In total, seven probes in the region 16 
demonstrated significantly increased DNA methylation after correcting for 208 tests (P < 2.4 17 
X 10
-4
), with the top PFC DMP (cg22962123) being similarly hypermethylated with respect 18 
to Braak stage (Figure 1D; PFC: R = 0.36, P = 1.2 X 10
-7
; STG: R= 0.28, P=2.78 X 10
-4
). 19 
There was an overall consistent pattern of effect sizes across both brain regions for the 208 20 
probes in the HOXA neuropathology-associated region (Figure 1E; R = 0.76, P = 2.66 X 10
-21 
40
).  22 
 23 
3.2 Cortical neuropathology-associated hypermethylation in HOXA3 is observed in 24 
independent study cohorts 25 
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We next sought to replicate the observation of neuropathology-associated hypermethylation 1 
across these 208 probes in two independent, previously published data-sets. First we 2 
examined the “London” (Lunnon et al [6]) data-set, comprising Illumina 450K array data 3 
generated using matched PFC, STG, EC, CER and pre-mortem blood samples obtained from 4 
117 donors (described in [6]) (Supplementary Table 1). We observed a similar pattern of 5 
Braak-associated DNA methylation across this 208 probe region in the replication cohort in 6 
both the PFC (Figure 2A) and STG (Supplementary Figure 2), with a highly correlated 7 
effect size between cohorts in both brain regions (PFC: Figure 2B; R = 0.74, P = 2.27 X 10
-
8 
37
; STG: Supplementary Figure 3; R = 0.68, P = 1.87 X 10
-29
); 15 and six probes reaching 9 
our corrected significance threshold (P < 2.4 X 10
-4
) in the PFC and STG respectively. In 10 
contrast, no probes in this region reached the corrected significance threshold in the EC 11 
(Supplementary Figure 4) although the effect size was still correlated (R = 0.41, P = 1.23 X 12 
10
-9
). Similarly no probes reached the significance threshold in the CER (Supplementary 13 
Figure 5), or in pre-mortem whole blood collected in a subset (N=57) of the same individuals 14 
(Supplementary Figure 6), with no correlation of effect sizes in either the CER (R = 0.03, P 15 
= 0.639) or blood (R = 0.11, P = 0.138). This indicates that the association may be specific to 16 
only particular regions of the cortex.  17 
We subsequently assessed this region in the “ROS/MAP” (De Jager et al) data-set comprising 18 
of 740 PFC samples profiled on the Illumina 450K array (as described in Ref [7]) 19 
(Supplementary Table 1) observing a similar pattern of effects with highly-significant 20 
neuropathology-associated hypermethylation across probes in the HOXA genic region 21 
(Figure 2C), and a significant correlation of effect size with the same 208 probes in the PFC 22 
in the discovery cohort (Figure 2D; R = 0.80, P = 2.39 X 10
-48
). A Fisher’s combined P value 23 
of DNA methylation differences across this region in all three PFC datasets confirmed a 24 
clearly defined region of significant neuropathology-associated elevated DNA methylation, 25 
10 
 
with many individual DMPs passing the threshold for experiment-wide significance (Figure 1 
2E), and a consistent pattern of effects across the three cohorts (Supplementary Figure 7). 2 
The most significant DMP identified within the HOXA3 gene in our discovery cohort 3 
(cg22962123; Table 1A) was also the most significant DMP in our Fisher’s combined P 4 
value analysis (P = 1 X 10
-20
). A meta-analysis comparing Braak 0 to Braak VI demonstrated 5 
increased DNA methylation with respect to Braak stage across all cohorts in the PFC (Figure 6 
2F; P = 3.11 X 10
-18
). Together, our data suggests that DNA hypermethylation across the 7 
extended HOXA gene region is robustly associated with AD-related neuropathology in both 8 
the PFC and STG, with the strongest effects in the vicinity of HOXA3. 9 
 10 
4. Discussion 11 
We identified an extended region of elevated DNA methylation in the HOXA gene cluster 12 
that is associated with AD neuropathology, with consistent effects seen across three 13 
independent post-mortem brain sample cohorts. Although one previous study had 14 
demonstrated differential methylation at a single CpG within the HOXA gene cluster [7], and 15 
another identified a DMR spanning seven CpG sites [6], this represents the first study to 16 
illustrate that hypermethylation in this region extends to 208 DMPs, spanning approximately 17 
48.7Kb. Differential DNA methylation in the HOXA gene cluster has been previously 18 
reported in blood collected from Down syndrome (DS) individuals [22], which is interesting 19 
given that many DS individuals develop AD resulting from an additional copy of the APP 20 
gene due to trisomy on chromosome 21. The DS study demonstrated differential DNA 21 
methylation in 20 probes largely located within HOXA2. Of note, 17 of these probes were 22 
significantly hypermethylated in the PFC in our discovery (Mount Sinai) cohort. However 23 
none were differentially methylated in pre-mortem blood in the London (Lunnon et al) 24 
11 
 
cohort. In the context of other neurodegenerative disorders, one study that investigated 1 
microRNAs (miRNAs) targeting HOX genes in Huntington’s disease (HD) demonstrated 2 
increased levels of miRNAs related to HOXA5, HOXA10, HOXA11, HOXA-11AS, HOXA13 3 
and HOTAIRM1 in the prefrontal cortex in HD [23]. Although HOX genes encode potent 4 
transcription factors that play a critical role in embryonic development [24], a recent study in 5 
Drosophila also highlighted a potent protective function for Hox genes in neurons, 6 
implicating a role in neuro-protection [25] Interestingly, this study also highlighted how Hox 7 
genes act to maintain expression of the ankyrin locus, an important observation given our 8 
previous finding of altered DNA methylation in ANK1 in AD [6]. Indeed, to further explore 9 
this hypothesis we examined the correlation between DNA methylation levels at the most 10 
significant HOX probe identified in the current study (cg22962123) with the two ANK1 11 
DMPs that we previously identified to be associated with AD neuropathology (cg11823178 12 
and cg05066959) [6, 7] in the PFC, identifying a significant correlation with both ANK1 13 
probes (cg11823178: R = 0.24, P = 5.15 X 10
-10
; cg05066959: R = 0.20, P = 2.93 X 10
-8
). 14 
Although this correlation could reflect the association between both HOXA3 and ANK1 15 
probes with Braak stage, it could highlight a novel physiological mechanism, particularly as 16 
we still observed significant hypermethylation (P = 1.67 X 10
-5
) at our top HOXA probe 17 
(cg22962133), when controlling for levels of DNA methylation in the top ANK1 probe 18 
(cg11823178). Looking to the future, analyses of gene expression levels should be performed 19 
to facilitate the interpretation of the DNA methylation differences we observe in HOXA. To 20 
conclude, this study provides further evidence for altered epigenetic processes in the 21 
pathophysiology of AD and suggests that further work on the neuroprotective functions of 22 
HOX genes is warranted. 23 
 24 
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Table 1: Differentially methylated positions (DMPs) and differentially methylated regions (DMRs) associated with Braak stage in the prefrontal cortex 
(PFC). (A) The ten DMPs in PFC in the discovery (Mount Sinai) cohort that reached experiment-wide significance (P < 2.2 X 10
-7
) are shown, with annotation 
to chromosomal location (hg19), up/downstream genes (from GREAT annotation), P value from our quantitative association model and corrected DNA 
methylation difference (Δ) from Braak score 0 – VI (as a %). Also shown is the corresponding information in the matched superior temporal gyrus (STG) 
samples in the same cohort, and the matched brain regions (PFC, STG) in the London (Lunnon et al) cohort, demonstrating a nominally significant difference. 
A list of the 78 top-ranked PFC DMPs at a more relaxed threshold of P < 1 X 10
-5
 are given in Supplementary Table 2. (B) DMRs significantly associated 
with Braak stage in the PFC. Shown are all significantly associated regions (Sidak-corrected P value < 0.05) which contain three or more probes, with 
chromosomal location (hg19), up/downstream genes, number of probes in the significant region and Sidak corrected P value.  
 
 
 
 
 
 
 
 
 
 
A 
Probe Location 
Illumina 
Annotation 
GREAT Annotation 
Discovery (Mount Sinai) cohort  London (Lunnon et al) cohort 
Association with Braak Stage Association with Braak Stage 
PFC STG PFC STG 
Downstream Upstream Δ P Value Δ P Value Δ P Value Δ P Value 
cg22867816 4:16081205 PROM1 FGFBP2 (-116347)  PROM1 (+4118) -3.90 9.80E-09 -2.04 5.21E-03 - - - - 
cg06977285 7:18127468   HDAC9 (-408457)  PRPS1L1 (-59983) 3.66 2.02E-08 2.68 1.84E-04 - - 1.88 7.65E-03 
cg05783384 2:218843735   RUFY4 (-90242)  TNS1 (-34885) 7.42 4.46E-08 5.55 8.01E-05 3.26 7.76E-03 3.83 6.48E-04 
cg07349815 3:123751269   CCDC14 (-70706)  KALRN (-62258) 5.15 6.70E-08 - - 2.15 0.02 1.83 7.35E-03 
cg21806242 11:72532891 ATG16L2 ATG16L2 (+7539)  FCHSD2 (+320414) 8.51 7.02E-08 5.55 4.08E-04 5.22 3.86E-04 4.62 1.10E-03 
cg03834767 7:90794392 CDK14 FZD1 (-99390)  CDK14 (+455681) -4.50 8.13E-08 - - - - - - 
cg13935577 12:107974897 BTBD11 PWP1 (-104611)  BTBD11 (+262708) 9.11 8.45E-08 5.27 1.49E-03 4.02 5.10E-03 3.73 0.02 
cg27078890 11:128457459 ETS1 ETS1 (-23)   4.85 9.86E-08 - - 2.09 0.02 - - 
cg22962123 7:27153605 HOXA3 HOXA2 (-11176)  HOXA3 (+5608) 7.88 1.20E-07 5.12 2.78E-04 5.62 2.24E-05 5.18 5.21E-04 
cg26199857 12:54764265 ZNF385A GPR84 (-5995)  ZNF385A (+20816) 5.43 1.87E-07 4.44 1.02E-03 2.62 0.03 - - 
 
 
 
B 
Chr Start End Gene Annotation GREAT Annotation 
Number 
of 
Probes 
Šidák 
corrected slk 
P Value 
chr11 2321770 2323247 C11ORF21 TSPAN32 (-734)  C11orf21 (+634) 27 3.20E-11 
chr7 27153580 27153944 HOXA3 HOXA2 (-11332)  HOXA3 (+5452) 7 1.19E-09 
chr7 27154262 27155234 HOXA3 HOXA2 (-12318)  HOXA3 (+4466) 16 4.31E-09 
chr7 27169957 27171401 HOXA4 HOXA4 (-261)   21 2.13E-08 
chr11 315908 316456 IFITM1 Closest IFITM1 (+2329)  IFITM3 (+4868) 5 4.02E-08 
chr12 58119915 58120237 AGAP2 AGAP2 (+11953)  OS9 (+32172) 6 1.22E-07 
chr7 27183133 27184853 HOXA5/HOXA-AS3 HOXA5 (-706)   42 2.19E-06 
chr5 78985425 78985900 CMYA5 CMYA5 (-37)   10 2.31E-06 
chr19 10736006 10736448 SLC44A2 SLC44A2 (+293)   8 3.68E-06 
chr19 39086733 39087186 MAP4K1 MAP4K1 (+21604)  RYR1 (+162490) 4 4.94E-06 
chr6 10556147 10556523 GCNT2 GCNT6 (-77658)  GCNT2 (+27746) 3 2.93E-05 
chr3 194014592 194015171 GRM2 Closest CPN2 (+57175)  HES1 (+160948) 4 3.24E-05 
chr4 184908351 184909018 STOX2 STOX2 (+82176)  ENPP6 (+230429) 8 3.60E-05 
chr7 27145972 27146445 HOXA3 HOXA2 (-3779)   5 4.11E-05 
chr17 46388390 46388465 SKAP1 SKAP1 (+119124)  SNX11 (+203508) 3 4.77E-05 
chr17 74475240 74475402 RHBDF2 RHBDF2 (+22168)  AANAT (+25888) 5 8.13E-05 
chr3 51740741 51741280 GRM2 GRM2 (-75)   6 1.93E-04 
chr17 41363502 41364121 NBR1/TMEM106A TMEM106A (-82)   11 3.04E-04 
chr17 43318610 43319371 FMNL1 FMNL1 (+19835)  SPATA32 (+20488) 6 4.51E-04 
chr7 158281410 158281613 PTPRN2 PTPRN2 (+98859)   3 4.66E-04 
chr13 43565901 43566496 EPSTI1 DNAJC15 (-31140)  TNFSF11 (+417910) 9 4.72E-04 
chr20 57582787 57583520 CTSZ Closest CTSZ (-852)   18 6.82E-04 
chr19 3179545 3180035 S1PR4 NCLN (-5808)  S1PR4 (+1054) 4 7.59E-04 
chr22 37608611 37608819 SSTR3 Closest SSTR3 (-353)   3 8.84E-04 
chr13 113698408 113699016 MCF2L F7 (-61409)  MCF2L (+75177) 13 9.15E-04 
chr9 34457129 34457500 FAM219A DNAI1 (-1518)   4 1.05E-03 
chr17 75315081 75315567 SEPT9 TNRC6C (-685813)  SEPT9 (+37832) 8 1.28E-03 
chr16 29674618 29675214 SPN SPN (+336)   6 1.77E-03 
chr1 55246867 55247408 TTC22 PARS2 (-16951)  DHCR24 (+105753) 5 2.45E-03 
chr12 58132558 58133008   AGAP2 (-754)   3 3.00E-03 
chr7 27138712 27138974 HOTAIRM1 HOXA1 (-3250)   4 3.19E-03 
chr16 67686832 67687392 RLTRP ACD (+7534)  RLTPR (+8290) 4 3.59E-03 
chr12 58129855 58130410 AGAP2 AGAP2 (+1896)  OS9 (+42229) 4 4.42E-03 
chr17 19314299 19314618 RNF112 RNF112 (-48)   6 9.80E-03 
chr15 40583227 40583422 PLCB2 PLCB2 (+16798)  PAK6 (+51704) 3 0.01922 
chr15 38988533 38988860 C15ORF53 THBS1 (-884597)  RASGRP1 (-131690) 4 0.01974 
chr16 1482952 1483192 CCDC154 Closest C16orf91 (-3727)   3 0.02843 
 
Supplementary Figure 1: DNA methylation of probes within the HOXA3 gene are highly correlated. 
Using the R package coMET [17] we saw that the majority of probes within the HOXA3 gene are highly 
correlated with each other.   
Supplementary Figure 2: A similar pattern of association between DNA methylation in the HOXA gene 
cluster and braak stage was seen in the STG in the London (Lunnon et al) cohort. Red circles indicate 
increased DNA methylation in disease (≥1% between Braak 0 and Braak VI), green circles indicate decreased 
DNA methylation in disease (≥1% between Braak 0 and Braak VI) and black circles indicate DNA 
methylation differences <1% between Braak 0 and Braak VI. The red line indicates experiment-wide 
significance (P = 2.2 X 10-7), whilst the blue line indicates significance after correcting for 208 tests (P = 2.4 
X 10-4). 
Supplementary Figure 3: Conserved methylation patterns in AD brain are observed across the 
HOXA gene cluster in the STG in the London (Lunnon et al) cohort. Methylation patterns in AD STG 
across the 208 probes in the HOXA gene are highly correlated between the discovery (Mount Sinai) cohort 
and samples from the London (Lunnon et al) cohort (R = 0.68, P = 1.87 X 10-29). 
Supplementary Figure 4: No association between DNA hypermethylation in the HOXA gene cluster 
and braak stage was seen in the EC in the London (Lunnon et al) cohort. Red circles indicate increased 
DNA methylation in disease (≥1% between Braak 0 and Braak VI), green circles indicate decreased DNA 
methylation in disease (≥1% between Braak 0 and Braak VI) and black circles indicate DNA methylation 
differences <1% between Braak 0 and Braak VI. The red line indicates experiment-wide significance (P = 
2.2 X 10-7), whilst the blue line indicates significance after correcting for 208 tests (P = 2.4 X 10-4). 
Supplementary Figure 5: No association between DNA hypermethylation in the HOXA gene cluster and 
braak stage was seen in the CER in the London (Lunnon et al) cohort. Red circles indicate increased 
DNA methylation in disease (≥1% between Braak 0 and Braak VI), green circles indicate decreased DNA 
methylation in disease (≥1% between Braak 0 and Braak VI) and black circles indicate DNA methylation 
differences <1% between Braak 0 and Braak VI. The red line indicates experiment-wide significance (P = 2.2 
X 10-7), whilst the blue line indicates significance after correcting for 208 tests (P = 2.4 X 10-4).            
     
 
 
 
 
Supplementary Figure 6: No association between DNA hypermethylation  in the HOX gene cluster and 
braak stage was seen in pre-mortem blood in the London (Lunnon et al) cohort. Red circles indicate 
increased DNA methylation in disease (≥1% between Braak 0 and Braak VI), green circles indicate decreased 
DNA methylation in disease (≥1% between Braak 0 and Braak VI) and black circles indicate DNA methylation 
differences <1% between Braak 0 and Braak VI. The red line indicates experiment-wide significance (P = 2.2 
x 10-7), whilst the blue line indicates significance after correcting for 208 tests (P = 2.4 X 10-4). 
            
 
 
Supplementary Figure 7: A consistent pattern of effect size was observed across the HOXA cluster in 
all three cohorts 
Control
Middle Stage 
AD
Late Stage Control Middle Stage AD Late Stage Control
Middle Stage 
AD
Late Stage 
Number of Cases 60 43 44 29 18 66 151 424 165
Gender (M/F) 32/28 13/30 12/32 13/16 7/11 26/40 75/76 148/276 46/119
Age at Death (±SD) 82.0 (7.56) 82.7 (6.55) 88.0 (7.53) 77.6 (12.80) 88.5 (5.20) 85.4 (8.13) 83.6 (7.19) 88.8 (6.32) 89.8 (5.22)
Braak Score 0-II III-IV V-VI 0-II III-IV V-VI 0-II III-IV V-VI
Brain Regions investigated
ROS/MAP (De Jager et al ) cohort
Supplementary Table 1: Demographics for samples used within the study. Abbreviations: SD (standard deviation); PFC (prefrontal cortex); STG 
(superior temporal gyrus); CER (cerebellum); EC (entorhinal cortex).
PFC, STG PFC, STG, CER, EC, Blood PFC
Discovery (Mount Sinai) cohort London (Lunnon et al ) cohort
Δ
P  Value
∆
P  Value
∆
P  Value
∆
P  Value
cg22867816 4:16081205 PROM1 FGFBP2 (-116347)  PROM1 (+4118) -3.90 9.80E-09 -2.04 5.21E-03 - - - -
cg06977285 7:18127468 HDAC9 (-408457)  PRPS1L1 (-59983) 3.66 2.02E-08 2.68 1.84E-04 - - 1.88 7.65E-03
cg05783384 2:218843735 RUFY4 (-90242)  TNS1 (-34885) 7.42 4.46E-08 5.55 8.01E-05 3.26 7.76E-03 3.83 6.48E-04
cg07349815 3:123751269 CCDC14 (-70706)  KALRN (-62258) 5.15 6.70E-08 - - 2.15 0.02 1.83 7.35E-03
cg21806242 11:72532891 ATG16L2 ATG16L2 (+7539)  FCHSD2 (+320414) 8.51 7.02E-08 5.55 4.08E-04 5.22 3.86E-04 4.62 1.10E-03
cg03834767 7:90794392 CDK14 FZD1 (-99390)  CDK14 (+455681) -4.50 8.13E-08 - - - - - -
cg13935577 12:107974897 BTBD11 PWP1 (-104611)  BTBD11 (+262708) 9.11 8.45E-08 5.27 1.49E-03 4.02 5.10E-03 3.73 0.02
cg27078890 11:128457459 ETS1 ETS1 (-23) 4.85 9.86E-08 - - 2.09 0.02 - -
cg22962123 7:27153605 HOXA3 HOXA2 (-11176)  HOXA3 (+5608) 7.88 1.20E-07 5.12 2.78E-04 5.62 2.24E-05 5.18 5.21E-04
cg26199857 12:54764265 ZNF385A GPR84 (-5995)  ZNF385A (+20816) 5.43 1.87E-07 4.44 1.02E-03 2.62 0.03 - -
cg19802390 1:2840177 MMEL1 (-275749)  ACTRT2 (-97868) -4.66 3.73E-07 -2.44 6.27E-03 -1.97 5.23E-03 -1.46 0.01
cg02317313 12:122235206 LOC338799 RHOF (-3039) 5.32 4.08E-07 3.76 4.82E-03 3.23 1.83E-03 2.28 0.04
cg06574422 12:111181673 PPP1CC PPP1CC (-930) 4.21 4.90E-07 2.00 0.05 - - - -
cg01301319 7:27153580 HOXA3 HOXA2 (-11151)  HOXA3 (+5633) 4.87 5.06E-07 3.99 5.33E-04 3.46 5.75E-04 3.83 3.32E-04
cg16406967 7:27155036 HOXA3 HOXA2 (-12607)  HOXA3 (+4177) 7.99 5.12E-07 4.18 0.01 4.84 6.61E-05 4.43 5.23E-04
cg14557202 12:54764371 ZNF385A GPR84 (-6101)  ZNF385A (+20710) 7.02 5.96E-07 4.40 4.04E-03 3.18 0.02 - -
cg23377551 12:58130154 AGAP2 AGAP2 (+1874)  OS9 (+42251) 5.68 6.81E-07 4.38 8.28E-04 3.28 6.01E-03 2.87 4.76E-03
cg09642525 16:85320701 GSE1 (-326120)  KIAA0513 (+223884) 2.22 7.76E-07 1.17 0.02 - - - -
cg07315426 7:158281537 PTPRN2 PTPRN2 (+98833) 3.64 8.41E-07 1.59 0.04 - - - -
cg14103343 19:49220223 MAMSTR MAMSTR (+2754)  FUT2 (+20992) 4.25 8.44E-07 2.23 0.02 1.83 0.02 1.76 0.03
cg16385330 4:151503878 LRBA;MAB21L2 MAB21L2 (+802) 4.84 8.54E-07 3.22 2.95E-03 - - - -
cg08991643 3:194014928 CPN2 (+57128)  HES1 (+160995) 6.83 9.11E-07 4.75 6.38E-04 - - - -
cg07061298 7:27153847 HOXA3 HOXA2 (-11418)  HOXA3 (+5366) 4.87 1.17E-06 3.11 3.63E-03 4.14 2.75E-05 3.56 2.32E-04
cg04682967 22:37608626 SSTR3 SSTR3 (-265) 4.03 1.17E-06 2.45 2.73E-03 1.40 0.03 - -
cg23120601 15:40583227 PLCB2 PLCB2 (+16895)  PAK6 (+51607) 6.08 1.38E-06 2.72 0.05 3.94 1.86E-03 2.16 0.05
cg02292809 6:17101478 STMND1 (-1010) -2.35 1.44E-06 -1.27 0.02 - - - -
cg12234455 19:49220235 MAMSTR MAMSTR (+2742)  FUT2 (+21004) 4.54 1.66E-06 2.80 5.94E-03 1.94 0.02 1.68 0.04
cg02124912 1:202091933 GPR37L1 GPR37L1 (-52) 4.25 1.68E-06 2.94 3.75E-03 2.23 0.04 3.24 2.66E-04
cg17400113 15:93617146 RGMA RGMA (-55) -3.05 1.69E-06 -1.93 4.72E-03 - - -1.40 0.04
cg23950714 5:176935364 DOK3 PDLIM7 (-10781)  DOK3 (+1493) -5.76 1.80E-06 -4.31 9.49E-04 -3.48 2.26E-03 -2.60 0.03
cg14769703 10:43818695 RASGEF1A (-114064)  FXYD4 (-48394) 4.39 2.05E-06 2.63 1.34E-03 - - - -
Supplementary Table 2: Probes associated with Braak stage in the PFC in the discovery (Mount Sinai) cohort at P  < 1 X 10-5 . Shown are chromosomal 
location (hg19), up/downstream genes from Illumina and GREAT annotation, P Value from our quantitative model, difference (∆) in corrected DNA 
methylation from Braak score 0 – VI (as a %). Also shown are the corresponding statistics in the matched STG samples in the same cohort, and the matched 
brain regions (PFC, STG) in the London (Lunnon et al ) cohort, demonstrating a nominally significant difference. Abbreviations: PFC (prefrontal cortex); STG 
(superior temporal gyrus).
Probe
Association with Braak Stage
PFC STGPFC STG
Association with Braak Stage
Discovery (Mount Sinai) Cohort London (Lunnon et al ) Cohort
GREAT AnnotationIllumina AnnotationLocation
Δ
P  Value
∆
P  Value
∆
P  Value
∆
P  Value
Probe
Association with Braak Stage
PFC STGPFC STG
Association with Braak Stage
Discovery (Mount Sinai) Cohort London (Lunnon et al ) Cohort
GREAT AnnotationIllumina AnnotationLocation
cg01463828 8:22446721 PDLIM2 ENSG00000248235 (-65) 7.75 2.06E-06 4.63 2.53E-03 4.23 3.20E-03 4.98 1.01E-03
cg17113856 6:32120895 PPT2;PRRT1 PRRT1 (-1167)  PPT2-EGFL8 (-1103) 4.01 2.20E-06 2.75 9.47E-04 2.30 5.52E-03 2.36 1.03E-03
cg26022064 7:98739782 SMURF1 SMURF1 (+1940)  TRRAP (+263670) 4.40 2.26E-06 3.37 1.77E-03 2.59 4.70E-03 2.67 1.93E-03
cg04874795 16:86477638 FOXF1 (-66494)  IRF8 (+545230) -6.18 2.37E-06 -2.90 0.03 -4.23 3.53E-05 -3.00 3.50E-03
cg05287480 7:27176127 HOXA4 (-5710)  HOXA5 (+7159) 3.30 2.46E-06 1.84 0.02 2.59 2.14E-04 1.46 9.83E-03
cg19048532 7:27148002 HOXA3 HOXA2 (-5573)  HOXA3 (+11211) 6.55 2.52E-06 4.48 9.41E-04 3.85 9.47E-04 3.37 9.47E-03
cg08578641 9:34457440 C9orf25;DNAI1 DNAI1 (-1392) 5.24 2.56E-06 2.81 0.02 2.90 4.06E-03 2.87 5.08E-04
cg09298818 12:111181546 PPP1CC PPP1CC (-803) 2.11 2.82E-06 1.57 7.15E-04 - - - -
cg01353646 12:58132733 AGAP2 AGAP2 (-705) 5.47 3.20E-06 3.27 9.99E-03 3.23 4.52E-03 - -
cg14573448 7:27165187 HOXA3 HOXA3 (-5974)  HOXA4 (+5230) 4.28 3.25E-06 2.04 0.02 - - - -
cg12163800 17:74475355 RHBDF2 RHBDF2 (+22133)  AANAT (+25923) 4.42 3.53E-06 2.51 0.02 2.23 2.78E-03 2.71 1.67E-03
cg27228136 22:37608819 SSTR3 SSTR3 (-458) 3.39 3.63E-06 1.58 0.04 - - - -
cg13852561 9:140302117 EXD3 NRARP (-105415)  EXD3 (+15596) 3.92 3.67E-06 2.42 5.64E-03 - - - -
cg08000731 11:316247 IFITM1 (+2395)  IFITM3 (+4802) 8.32 4.12E-06 6.39 5.81E-04 - - - -
cg13714797 9:7103479 KDM4C KDM4C (+345824)  C9orf123 (+696587) 5.88 4.20E-06 4.00 7.71E-05 - - - -
cg20864214 11:73054121 ARHGEF17 RELT (-33187)  ARHGEF17 (+34788) 5.91 4.39E-06 3.26 0.02 4.92 3.95E-05 4.13 1.02E-03
cg08230957 19:39087186 MAP4K1 MAP4K1 (+21377)  RYR1 (+162717) 4.72 4.51E-06 3.57 2.09E-03 2.87 2.46E-03 2.49 0.01
cg23618477 6:169334872 THBS2 (+319266)  SMOC2 (+493042) -7.91 4.52E-06 -4.58 5.99E-03 -4.20 9.68E-04 -4.22 1.10E-03
cg17067993 17:38721675 CCR7 CCR7 (+48) -2.31 4.60E-06 - - - - - -
cg21987515 4:153274118 FBXW7 PET112 (-591944)  FBXW7 (+183134) 3.99 4.76E-06 - - - - - -
cg08441803 17:46388390 SKAP1 SKAP1 (+119161)  SNX11 (+203471) 3.38 4.82E-06 1.80 0.02 - - - -
cg12155963 7:150147553 GIMAP8 GIMAP8 (-164) -4.11 4.87E-06 - - - - - -
cg14147151 9:138948000 NACC2 NACC2 (-5575)  C9orf69 (+62708) -4.96 4.94E-06 -3.37 5.56E-03 - - - -
cg13313598 6:136672985 MAP7 BCLAF1 (-61997)  MAP7 (+174624) 4.51 5.15E-06 2.54 0.03 2.16 0.03 2.66 1.64E-03
cg18702012 10:126106555 OAT OAT (+949) 3.46 5.15E-06 2.37 4.60E-03 - - - -
cg24550149 1:55246954 TTC22 PARS2 (-16768)  DHCR24 (+105936) 4.75 5.26E-06 3.18 3.44E-03 3.48 2.78E-04 - -
cg14288213 19:18703034 C19orf60 C19orf60 (+3500)  CRLF1 (+14625) -4.15 5.39E-06 -2.22 9.65E-03 - - - -
cg00795125 7:5409340 TNRC18 TNRC18 (+53836)  SLC29A4 (+86780) -2.64 5.69E-06 -1.51 8.49E-03 - - - -
cg08924415 8:144902836 PUF60 SCRIB (-5288)  PUF60 (+9192) 3.81 5.77E-06 2.86 3.95E-03 - - - -
cg23347323 19:45912637 ERCC1;CD3EAP PPP1R13L (-3031) -2.95 6.00E-06 -1.71 6.28E-03 - - - -
cg09596958 12:58132105 AGAP2 AGAP2 (-77) 7.85 6.45E-06 3.56 0.05 5.86 4.20E-04 4.06 6.91E-03
cg17006136 4:186559412 SORBS2 PDLIM3 (-102751)  SORBS2 (+318393) -6.02 6.66E-06 -3.08 0.02 -3.03 1.33E-03 -3.50 3.28E-04
cg21730858 6:138806320 NHSL1 ECT2L (-310742)  HEBP2 (+80965) 4.58 7.15E-06 2.42 0.01 - - - -
cg06830450 12:58121004 LOC100130776;AGAP2 AGAP2 (+11024)  OS9 (+33101) 3.89 7.50E-06 2.61 0.01 1.84 0.02 - -
cg22729726 1:3123854 PRDM16 ARHGEF16 (-247135)  PRDM16 (+138080) -3.41 7.51E-06 -2.09 0.03 - - -1.92 5.41E-03
cg21663431 19:10736355 SLC44A2 SLC44A2 (+422) 6.08 7.92E-06 3.33 0.02 4.26 5.86E-04 3.70 1.45E-03
cg23184252 12:125139714 NCOR2 (-159917)  SCARB1 (+208678) 3.07 7.92E-06 - - 2.04 8.31E-04 1.05 0.02
cg18680977 7:27155039 HOXA3 HOXA2 (-12610)  HOXA3 (+4174) 8.23 8.15E-06 5.95 1.54E-03 6.04 1.50E-04 5.52 6.22E-04
Δ
P  Value
∆
P  Value
∆
P  Value
∆
P  Value
Probe
Association with Braak Stage
PFC STGPFC STG
Association with Braak Stage
Discovery (Mount Sinai) Cohort London (Lunnon et al ) Cohort
GREAT AnnotationIllumina AnnotationLocation
cg15751131 7:140090416 SLC37A3 JHDM1D (-213582)  SLC37A3 (+7932) -4.05 8.20E-06 -2.16 0.04 -2.35 7.73E-03 -1.57 0.03
cg26681211 11:20385635 HTATIP2 HTATIP2 (+347) -1.81 8.28E-06 - - - - - -
cg19759481 7:27183401 HOXA5 HOXA5 (-115) 3.05 9.05E-06 1.34 0.04 1.60 0.01 - -
cg14030904 6:149806732 ZC3H12D ZC3H12D (-536) -4.34 9.11E-06 -2.72 5.87E-03 -2.07 0.01 -1.84 5.34E-03
cg14795572 12:58131681 AGAP2 AGAP2 (+347) 5.02 9.18E-06 - - 4.22 7.40E-04 3.21 1.97E-03
cg07737292 16:56892460 MIR138-2 SLC12A3 (-6658)  NUP93 (+128444) -2.72 9.18E-06 - - -1.74 5.18E-03 - -
cg02411995 16:4851344 ROGDI SEPT12 (-12823)  ROGDI (+1606) 3.54 9.57E-06 2.81 7.67E-04 - - - -
cg24928023 21:45395775 AGPAT3 TRAPPC10 (-36424)  AGPAT3 (+50887) 5.83 9.79E-06 4.87 2.65E-03 - - 3.01 8.61E-03
cg24527008 5:177870233 COL23A1 PHYKPL (-210448)  COL23A1 (+147322) -3.83 9.93E-06 - - -1.87 6.11E-03 - -
